Baker Jackie, Ajani Jaffer, Scotté Florian, Winther Dorte, Martin Miguel, Aapro Matti S, von Minckwitz Gunter
University of Texas MD Anderson Cancer Center, Gastrointestinal Medical Oncology, Faculty Center, Houston, TX 77030, USA.
Eur J Oncol Nurs. 2009 Feb;13(1):49-59. doi: 10.1016/j.ejon.2008.10.003. Epub 2009 Feb 7.
Docetaxel is an effective treatment approved in five key cancers, but its effectiveness in clinical practice can be compromised by sub-optimal side-effect management. The aim of this review was to investigate the extent of the published work on specific docetaxel-related side effects and to provide, where possible, evidence-based recommendations for their prevention and management. PubMed and the American Society of Clinical Oncology (ASCO) databases were systematically searched for articles published in English over the past 5 years and 2 years, respectively, and pertaining to six side effects identified as being common to the majority of docetaxel regimens and indications and of particular relevance to the oncology nurse. The Cochrane library was also searched. A total of 103 citations were identified, 14 of which discussed strategies for the prevention or management of febrile neutropenia (n=6), hypersensitivity reactions (3), fluid retention (1) and nail changes (4). No articles were identified that related to asthenia or neuropathy. Based on the literature review, evidence/guidelines-based advice for the use of G-CSF in febrile neutropenia is provided. The evidence base with respect to the other side effects does not permit the formulation of recommendations. It is the experience of the authors, however, that the severity of symptoms experienced by patients is generally mild and the side effects are for the most part easily managed with prophylactic and supportive care measures. It is, therefore, important to share and build on experiences, through research and discussion, to maximise the healthcare professional's ability to offer the best standard of care to patients.
多西他赛是一种已被批准用于治疗五种主要癌症的有效药物，但其在临床实践中的有效性可能会因副作用管理欠佳而受到影响。本综述的目的是调查已发表的关于多西他赛特定相关副作用的研究范围，并尽可能提供基于证据的预防和管理建议。分别系统检索了PubMed和美国临床肿瘤学会（ASCO）数据库中过去5年和2年以英文发表的、与六种被确定为大多数多西他赛治疗方案和适应证所共有的、且对肿瘤护士特别相关的副作用相关的文章。还检索了Cochrane图书馆。共识别出103篇文献，其中14篇讨论了发热性中性粒细胞减少（n = 6）、过敏反应（3篇）、液体潴留（1篇）和指甲改变（4篇）的预防或管理策略。未识别出与乏力或神经病变相关的文章。基于文献综述，提供了关于在发热性中性粒细胞减少中使用粒细胞集落刺激因子（G-CSF）的基于证据/指南的建议。关于其他副作用的证据基础不允许制定建议。然而，作者的经验是，患者所经历症状的严重程度通常较轻，并且大多数副作用通过预防性和支持性护理措施很容易得到管理。因此，通过研究和讨论分享并借鉴经验，以最大限度地提高医疗专业人员为患者提供最佳护理标准的能力非常重要。
